{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:35:50Z","timestamp":1780392950662,"version":"3.54.1"},"reference-count":57,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T00:00:00Z","timestamp":1618012800000},"content-version":"vor","delay-in-days":99,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004562","name":"Ministry of Higher Education and Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004562","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Despite advances in the treatment of cancers over the last years, treatment options for patients with recurrent glioblastoma (rGBM) remain limited with poor outcomes. Many regimens have been investigated in clinical trials; however, there is a lack of knowledge on comparative effectiveness. The aim of this systematic review is to provide an overview of existing treatment strategies and to estimate the relative efficacy of these regimens in terms of progression-free survival (PFS) and overall survival (OS).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a systematic review to identify randomized controlled trials (RCTs) investigating any treatment regimen in adult patients suffering from rGBM. Connected studies reporting at least one of our primary outcomes were included in a Bayesian network meta-analysis (NMA) estimating relative treatment effects.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Forty RCTs fulfilled our inclusion criteria evaluating the efficacy of 38 drugs as mono- or combination therapy. Median OS ranged from 2.9 to 18.3 months; median PFS ranged from 0.7 to 6 months. We performed an NMA including 24 treatments that were connected within a large evidence network. Our NMA indicated improvement in PFS with most bevacizumab (BV)-based regimens compared to other regimens. We did not find any differences in OS between treatments.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This systematic review provides a comprehensive overview of existing treatment options for rGBM. The NMA provides relative effects for many of these treatment regimens, which have not been directly compared in RCTs. Overall, outcomes for patients with rGBM remain poor across all treatment options, highlighting the need for innovative treatment options.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/noajnl\/vdab052","type":"journal-article","created":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T07:52:45Z","timestamp":1618041165000},"source":"Crossref","is-referenced-by-count":15,"title":["Systematic review and network meta-analysis of the efficacy of existing treatments for patients with recurrent glioblastoma"],"prefix":"10.1093","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8478-8055","authenticated-orcid":false,"given":"Anna","family":"Schritz","sequence":"first","affiliation":[{"name":"Competence Center for Methodology and Statistics, Department of Population Health, Luxembourg Institute of Health, Strassen, Luxembourg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nassera","family":"Aouali","sequence":"additional","affiliation":[{"name":"Clinical and Epidemiological Investigation Center, Department of Population Health, Luxembourg Institute of Health, Strassen, Luxembourg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6500-0034","authenticated-orcid":false,"given":"Aur\u00e9lie","family":"Fischer","sequence":"additional","affiliation":[{"name":"Clinical and Epidemiological Investigation Center, Department of Population Health, Luxembourg Institute of Health, Strassen, Luxembourg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7723-0304","authenticated-orcid":false,"given":"Coralie","family":"Dessenne","sequence":"additional","affiliation":[{"name":"Department of Population Health, Luxembourg Institute of Health, Strassen, Luxembourg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roisin","family":"Adams","sequence":"additional","affiliation":[{"name":"National Centre for Pharmacoeconomics, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0157-2257","authenticated-orcid":false,"given":"Guy","family":"Berchem","sequence":"additional","affiliation":[{"name":"Department of Hemato-Oncology, Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg"},{"name":"Luxembourg Institute of Health, Strassen, Luxembourg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5401-1958","authenticated-orcid":false,"given":"Laetitia","family":"Huiart","sequence":"additional","affiliation":[{"name":"Department of Population Health, Luxembourg Institute of Health, Strassen, Luxembourg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4753-1709","authenticated-orcid":false,"given":"Susanne","family":"Schmitz","sequence":"additional","affiliation":[{"name":"Competence Center for Methodology and Statistics, Department of Population Health, Luxembourg Institute of Health, Strassen, Luxembourg"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,4,9]]},"reference":[{"issue":"4","key":"2021070810463119500_CIT0001","doi-asserted-by":"crossref","first-page":"629","DOI":"10.4103\/jnrp.jnrp_168_17","article-title":"A simplified overview of world health organization classification update of central nervous system tumors 2016","volume":"8","author":"Gupta","year":"2017","journal-title":"J Neurosci Rural Pract"},{"key":"2021070810463119500_CIT0002","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol."},{"issue":"1","key":"2021070810463119500_CIT0003","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s11060-017-2564-z","article-title":"Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis","volume":"135","author":"van Linde","year":"2017","journal-title":"J Neurooncol."},{"issue":"7","key":"2021070810463119500_CIT0004","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1093\/annonc\/mdx169","article-title":"Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma","volume":"28","author":"Qazi","year":"2017","journal-title":"Ann Oncol."},{"issue":"19","key":"2021070810463119500_CIT0005","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.2217\/fon.15.125","article-title":"Bevacizumab in recurrent glioblastoma: open issues","volume":"11","author":"Franceschi","year":"2015","journal-title":"Future Oncol."},{"issue":"8","key":"2021070810463119500_CIT0006","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.ejca.2012.02.004","article-title":"New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials","volume":"48","author":"Gorlia","year":"2012","journal-title":"Eur J Cancer."},{"issue":"11","key":"2021070810463119500_CIT0007","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1586\/14737175.2015.1101346","article-title":"Irinotecan-based regimens for recurrent glioblastoma multiforme: [corrected] a systematic review","volume":"15","author":"Abdel-Rahman","year":"2015","journal-title":"Expert Rev Neurother."},{"issue":"1","key":"2021070810463119500_CIT0008","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11060-018-03064-0","article-title":"Re-irradiation for recurrent glioblastoma (GBM): a systematic review and meta-analysis","volume":"142","author":"Kazmi","year":"2019","journal-title":"J Neurooncol."},{"issue":"10","key":"2021070810463119500_CIT0009","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s11912-019-0834-y","article-title":"How we treat recurrent glioblastoma today and current evidence","volume":"21","author":"Chaul-Barbosa","year":"2019","journal-title":"Curr Oncol Rep."},{"issue":"24","key":"2021070810463119500_CIT0010","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1200\/JCO.2010.30.0582","article-title":"Scale to predict survival after surgery for recurrent glioblastoma multiforme","volume":"28","author":"Park","year":"2010","journal-title":"J Clin Oncol."},{"key":"2021070810463119500_CIT0011","doi-asserted-by":"crossref","first-page":"100551","DOI":"10.1016\/j.inat.2019.100551","article-title":"Recurrent glioblastomas: should we operate a second and even a third time?","volume":"18","author":"Djamel-Eddine","year":"2019","journal-title":"Interdiscip Neurosurg"},{"issue":"3","key":"2021070810463119500_CIT0012","first-page":"1743","article-title":"The effect of re-operation on survival in patients with recurrent glioblastoma","volume":"35","author":"Franceschi","year":"2015","journal-title":"Anticancer Res."},{"issue":"28","key":"2021070810463119500_CIT0013","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","volume":"27","author":"Friedman","year":"2009","journal-title":"J Clin Oncol."},{"issue":"11","key":"2021070810463119500_CIT0014","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1634\/theoncologist.2009-0121","article-title":"FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme","volume":"14","author":"Cohen","year":"2009","journal-title":"Oncologist."},{"issue":"4","key":"2021070810463119500_CIT0015","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jnci.2016.07.001","article-title":"Management of glioblastoma after recurrence: a changing paradigm","volume":"28","author":"Mallick","year":"2016","journal-title":"J Egypt Natl Canc Inst."},{"issue":"1","key":"2021070810463119500_CIT0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ije\/31.1.1","article-title":"Where now for meta-analysis?","volume":"31","author":"Egger","year":"2002","journal-title":"Int J Epidemiol."},{"key":"2021070810463119500_CIT0017","volume-title":"Methods for meta-analysis in medical research","author":"Sutton","year":"2000"},{"issue":"20","key":"2021070810463119500_CIT0018","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons","volume":"23","author":"Lu","year":"2004","journal-title":"Stat Med."},{"issue":"7521","key":"2021070810463119500_CIT0019","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","article-title":"Simultaneous comparison of multiple treatments: combining direct and indirect evidence","volume":"331","author":"Caldwell","year":"2005","journal-title":"BMJ."},{"issue":"5","key":"2021070810463119500_CIT0020","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/j.1524-4733.2008.00347.x","article-title":"Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons","volume":"11","author":"Jansen","year":"2008","journal-title":"Value Health."},{"issue":"4","key":"2021070810463119500_CIT0021","doi-asserted-by":"crossref","first-page":"403","DOI":"10.6004\/jnccn.2011.0037","article-title":"Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis","volume":"9","author":"Wong","year":"2011","journal-title":"J Natl Compr Canc Netw."},{"key":"2021070810463119500_CIT0022","doi-asserted-by":"crossref","DOI":"10.25259\/SNI_152_2020","article-title":"Laser interstitial thermal therapy as an adjunct therapy in brain tumors: a meta-analysis and comparison with stereotactic radiotherapy","volume":"11","author":"de Franca","year":"2020","journal-title":"Surg Neurol Int"},{"issue":"9311","key":"2021070810463119500_CIT0023","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(02)08091-1","article-title":"Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials","volume":"359","author":"Group GM-aTG.","year":"2002","journal-title":"Lancet"},{"issue":"5","key":"2021070810463119500_CIT0024","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3892\/mco.2016.816","article-title":"Bevacizumab treatment for newly diagnosed glioblastoma: systematic review and meta-analysis of clinical trials","volume":"4","author":"Fu","year":"2016","journal-title":"Mol Clin Oncol."},{"key":"2021070810463119500_CIT0025","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.clineuro.2017.05.015","article-title":"The interventional effect of new drugs combined with the Stupp protocol on glioblastoma: a network meta-analysis","volume":"159","author":"Li","year":"2017","journal-title":"Clin Neurol Neurosurg."},{"issue":"42","key":"2021070810463119500_CIT0026","doi-asserted-by":"crossref","first-page":"69002","DOI":"10.18632\/oncotarget.10763","article-title":"A network meta-analysis: the overall and progression-free survival of glioma patients treated by different chemotherapeutic interventions combined with radiation therapy (RT)","volume":"7","author":"Qi","year":"2016","journal-title":"Oncotarget."},{"key":"2021070810463119500_CIT0027","author":"Wang","year":"2020"},{"issue":"4","key":"2021070810463119500_CIT0028","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med."},{"key":"2021070810463119500_CIT0029","year":"2019"},{"issue":"1","key":"2021070810463119500_CIT0030","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12874-018-0509-7","article-title":"The use of single armed observational data to closing the gap in otherwise disconnected evidence networks: a network meta-analysis in multiple myeloma","volume":"18","author":"Schmitz","year":"2018","journal-title":"BMC Med Res Methodol."},{"issue":"10","key":"2021070810463119500_CIT0031","doi-asserted-by":"crossref","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PLoS One."},{"key":"2021070810463119500_CIT0032","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ."},{"issue":"2","key":"2021070810463119500_CIT0033","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s11060-010-0403-6","article-title":"Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy","volume":"103","author":"Reardon","year":"2011","journal-title":"J Neurooncol."},{"key":"2021070810463119500_CIT0034","first-page":"vi1","article-title":"ACTR-56: a 2-part safety and exploratory efficacy randomised double-blind, placebo-controlled study of a 1:1 ratio of cannabidiol and delta9-tetrahydrocannabinol (CBD:THC) plus doseintense temozolomide in patients with recurrent glioblastoma multiforme (GBM)","author":"Short","year":"2017"},{"issue":"15","key":"2021070810463119500_CIT0035","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2017.35.15_suppl.2046","article-title":"A two-part safety and exploratory efficacy randomized double-blind, placebo-controlled study of a 1:1 ratio of the cannabinoids cannabidiol and delta-9-tetrahydrocannabinol (CBD: THC) plus dose-intense temozolomide in patients with recurrent glioblastoma multiforme (GBM)","volume":"35","author":"Twelves","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"2021070810463119500_CIT0036","first-page":"171","article-title":"Continuing or ceasing bevacizumab beyond progression in recurrent glioblastoma: an exploratory randomized phase II trial","volume":"4","author":"Hovey","year":"2017","journal-title":"Neurooncol Pract."},{"issue":"3","key":"2021070810463119500_CIT0037","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1200\/JCO.2015.64.7685","article-title":"Randomized, double-blind, placebo-controlled, multicenter phase II study of onartuzumab plus bevacizumab versus placebo plus bevacizumab in patients with recurrent glioblastoma: efficacy, safety, and hepatocyte growth factor and O(6)-Methylguanine-DNA methyltransferase biomarker analyses","volume":"35","author":"Cloughesy","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"2021070810463119500_CIT0038","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1634\/theoncologist.2018-0290","article-title":"A randomized Phase II trial (TAMIGA) evaluating the efficacy and safety of continuous bevacizumab through multiple lines of treatment for recurrent Glioblastoma","volume":"24","author":"Brandes","year":"2019","journal-title":"Oncologist."},{"issue":"9","key":"2021070810463119500_CIT0039","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(14)70314-6","article-title":"Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial","volume":"15","author":"Taal","year":"2014","journal-title":"Lancet Oncol."},{"issue":"10","key":"2021070810463119500_CIT0040","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.ejca.2015.03.025","article-title":"The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial","volume":"51","author":"Dirven","year":"2015","journal-title":"Eur J Cancer."},{"issue":"3","key":"2021070810463119500_CIT0041","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s11060-009-9976-3","article-title":"Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide","volume":"96","author":"Dresemann","year":"2010","journal-title":"J Neurooncol."},{"key":"2021070810463119500_CIT0042","first-page":"vi1","article-title":"ATIM-14. ALLIANCE A071101: a phase II randomized trial comparing the efficacy of heat shock protein peptide Complex-96 (HDPPC-96) vaccine given with bevacizumab versus bevacizumab alone in the treatment of surgically resectable recurrent glioblastoma","author":"Bloch","year":"2017"},{"key":"2021070810463119500_CIT0043","volume-title":"Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics Guidance for Industry. U.S. Department of Health and Human ServicesFood and Drug Administration Oncology Center of ExcellenceCenter for Drug Evaluation and Research (CDER)Center for Biologics Evaluation and Research (CBER). Clinical\/Medical; December 2018"},{"key":"2021070810463119500_CIT0044","article-title":"?","volume-title":"Progression-Free Survival: What Does it Mean for Psychological Well-Being or Quality of Life","author":"Gutman","year":"2013"},{"issue":"2","key":"2021070810463119500_CIT0045","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/bimj.201900339","article-title":"Component network meta-analysis compared to a matching method in a disconnected network: a case study","volume":"63","author":"R\u00fccker","year":"2020","journal-title":"Biometrical Journal"},{"issue":"7","key":"2021070810463119500_CIT0046","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.1990.8.7.1277","article-title":"Response criteria for phase II studies of supratentorial malignant glioma","volume":"8","author":"Macdonald","year":"1990","journal-title":"J Clin Oncol."},{"issue":"21","key":"2021070810463119500_CIT0047","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1200\/JCO.2017.72.7511","article-title":"Response assessment in neuro-oncology clinical trials","volume":"35","author":"Wen","year":"2017","journal-title":"J Clin Oncol."},{"issue":"11","key":"2021070810463119500_CIT0048","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group","volume":"28","author":"Wen","year":"2010","journal-title":"J Clin Oncol."},{"key":"2021070810463119500_CIT0049","first-page":"iii21","article-title":"OS10.3: randomized phase 3 study evaluating the efficacy and safety of Nivolumab vs Bevacizumab in patients with recurrent glioblastoma: checkmate 143","author":"Reardon","year":"2017"},{"key":"2021070810463119500_CIT0050","first-page":"v610","article-title":"LBA16: REGOMA: a randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib activity in relapsed glioblastoma patients","volume-title":"Madrid, Spain","author":"Lombardi","year":"2017"},{"issue":"1","key":"2021070810463119500_CIT0051","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1470-2045(18)30675-2","article-title":"Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"20","author":"Lombardi","year":"2019","journal-title":"Lancet Oncol."},{"issue":"7","key":"2021070810463119500_CIT0052","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1200\/JCO.2009.23.2595","article-title":"Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma","volume":"28","author":"Wick","year":"2010","journal-title":"J Clin Oncol."},{"issue":"11","key":"2021070810463119500_CIT0053","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1093\/neuonc\/nov104","article-title":"Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma","volume":"17","author":"Field","year":"2015","journal-title":"Neuro Oncol."},{"issue":"3","key":"2021070810463119500_CIT0054","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s11060-016-2195-9","article-title":"A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma","volume":"129","author":"Weathers","year":"2016","journal-title":"J Neurooncol."},{"issue":"1","key":"2021070810463119500_CIT0055","first-page":"1","article-title":"Approaches to interpreting and choosing the best treatments in network meta-analyses","volume":"6","author":"Mbuagbaw","year":"2017","journal-title":"J Syst Rev"},{"key":"2021070810463119500_CIT0056","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.3389\/fimmu.2019.02965","article-title":"The intriguing history of cancer immunotherapy","volume":"10","author":"Dobosz","year":"2019","journal-title":"Front Immunol."},{"issue":"3","key":"2021070810463119500_CIT0057","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","article-title":"Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma","volume":"25","author":"Cloughesy","year":"2019","journal-title":"Nat Med."}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdab052\/37014061\/vdab052.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/noa\/article-pdf\/3\/1\/vdab052\/38476012\/vdab052.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/noa\/article-pdf\/3\/1\/vdab052\/38476012\/vdab052.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T19:26:09Z","timestamp":1625772369000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdab052\/6219627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,1]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdab052","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,1,1]]},"published":{"date-parts":[[2021,1,1]]},"article-number":"vdab052"}}